Literature DB >> 9284814

Expression of gelatinase B and the extracellular matrix metalloproteinase inducer EMMPRIN in benign and malignant pigment cell lesions of the skin.

J J van den Oord1, L Paemen, G Opdenakker, C de Wolf-Peeters.   

Abstract

By the degradative effect on basement membrane collagen type IV, matrix metalloproteinases (MMPs) or gelatinases are important in the early invasion of malignant tumors. These enzymes may be released by the tumor cells themselves or may be derived from nearby fibroblasts that have been stimulated by the extracellular MMP inducer EMMPRIN. We studied the distribution of 92-kd gelatinase B (MMP-9) and of EMMPRIN in 33 benign and 41 malignant, paraffin-embedded pigment cell lesions using immunohistochemistry and monoclonal antibodies. In benign pigment cell lesions, EMMPRIN but not gelatinase B was expressed in cellular blue nevi whereas all other benign lesions, including common blue nevi, were negative. In malignant melanomas (MMs), both gelatinase B and EMMPRIN were variably expressed in the pure and invasive radial growth phase but not in the vertical growth phase. All lentigo maligna cases and all metastatic lesions were negative. Of MMs with thickness < 1.6 mm, 63% expressed gelatinase B and 70% expressed EMMPRIN, whereas in MMs with > 1.6 mm thickness, only 10% expressed gelatinase B and only 25% expressed EMMPRIN. We conclude that early invasion of MM is associated with de novo expression of gelatinase B and EMMPRIN by neoplastic melanocytes. Expression of EMMPRIN and MMP-9 may be partly responsible for the stromal changes observed in thin MM. Their absence in the vertical growth phase and in metastatic lesions suggests that other factors are involved in tissue degradation during later stages of tumor progression in MM. The lack of both gelatinase B and EMMPRIN in lentigo maligna may contribute to the indolent behavior of this type of pigment cell lesion.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9284814      PMCID: PMC1857847     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  21 in total

1.  Gelatinase B in chronic synovitis: immunolocalization with a monoclonal antibody.

Authors:  B Grillet; J Dequeker; L Paemen; B Van Damme; G Opdenakker
Journal:  Br J Rheumatol       Date:  1997-07

2.  Tumor cell invasion inhibited by TIMP-2.

Authors:  A Albini; A Melchiori; L Santi; L A Liotta; P D Brown; W G Stetler-Stevenson
Journal:  J Natl Cancer Inst       Date:  1991-06-05       Impact factor: 13.506

3.  Mr 92,000 gelatinase release correlates with the metastatic phenotype in transformed rat embryo cells.

Authors:  E J Bernhard; R J Muschel; E N Hughes
Journal:  Cancer Res       Date:  1990-07-01       Impact factor: 12.701

Review 4.  Tumor invasion and metastasis: an imbalance of positive and negative regulation.

Authors:  L A Liotta; W G Stetler-Stevenson
Journal:  Cancer Res       Date:  1991-09-15       Impact factor: 12.701

5.  A study of tumor progression: the precursor lesions of superficial spreading and nodular melanoma.

Authors:  W H Clark; D E Elder; D Guerry; M N Epstein; M H Greene; M Van Horn
Journal:  Hum Pathol       Date:  1984-12       Impact factor: 3.466

6.  Surface antigens of melanomas and melanocytes defined by mouse monoclonal antibodies: specificity analysis and comparison of antigen expression in cultured cells and tissues.

Authors:  F X Real; A N Houghton; A P Albino; C Cordon-Cardo; M R Melamed; H F Oettgen; L J Old
Journal:  Cancer Res       Date:  1985-09       Impact factor: 12.701

7.  Induction of 103-kDa gelatinase/type IV collagenase by acidic culture conditions in mouse metastatic melanoma cell lines.

Authors:  Y Kato; Y Nakayama; M Umeda; K Miyazaki
Journal:  J Biol Chem       Date:  1992-06-05       Impact factor: 5.157

8.  Localization of messenger RNA for Mr 72,000 and 92,000 type IV collagenases in human skin cancers by in situ hybridization.

Authors:  C Pyke; E Ralfkiaer; P Huhtala; T Hurskainen; K Danø; K Tryggvason
Journal:  Cancer Res       Date:  1992-03-01       Impact factor: 12.701

9.  Expression of genes encoding type IV collagen-degrading metalloproteinases and tissue inhibitors of metalloproteinases in various human tumor cells.

Authors:  H Sato; Y Kida; M Mai; Y Endo; T Sasaki; J Tanaka; M Seiki
Journal:  Oncogene       Date:  1992-01       Impact factor: 9.867

Review 10.  Type IV collagenases in tumor invasion and metastasis.

Authors:  W G Stetler-Stevenson
Journal:  Cancer Metastasis Rev       Date:  1990-12       Impact factor: 9.264

View more
  30 in total

1.  Activated leukocyte cell adhesion molecule/CD166, a marker of tumor progression in primary malignant melanoma of the skin.

Authors:  L C van Kempen; J J van den Oord; G N van Muijen; U H Weidle; H P Bloemers; G W Swart
Journal:  Am J Pathol       Date:  2000-03       Impact factor: 4.307

Review 2.  Proteases in cutaneous malignant melanoma: relevance as biomarker and therapeutic target.

Authors:  Eleonore Fröhlich
Journal:  Cell Mol Life Sci       Date:  2010-08-05       Impact factor: 9.261

3.  Resistance of young gelatinase B-deficient mice to experimental autoimmune encephalomyelitis and necrotizing tail lesions.

Authors:  B Dubois; S Masure; U Hurtenbach; L Paemen; H Heremans; J van den Oord; R Sciot; T Meinhardt; G Hämmerling; G Opdenakker; B Arnold
Journal:  J Clin Invest       Date:  1999-12       Impact factor: 14.808

4.  Tumorigenic potential of extracellular matrix metalloproteinase inducer.

Authors:  S Zucker; M Hymowitz; E E Rollo; R Mann; C E Conner; J Cao; H D Foda; D C Tompkins; B P Toole
Journal:  Am J Pathol       Date:  2001-06       Impact factor: 4.307

5.  EMMPRIN (extracellular matrix metalloproteinase inducer) is a novel marker of poor outcome in serous ovarian carcinoma.

Authors:  Ben Davidson; Iris Goldberg; Aasmund Berner; Gunnar B Kristensen; Reuven Reich
Journal:  Clin Exp Metastasis       Date:  2003       Impact factor: 5.150

6.  Increased expression of extracellular matrix metalloproteinase inducer (CD147) in multiple myeloma: role in regulation of myeloma cell proliferation.

Authors:  B K Arendt; D K Walters; X Wu; R C Tschumper; P M Huddleston; K J Henderson; A Dispenzieri; D F Jelinek
Journal:  Leukemia       Date:  2012-03-30       Impact factor: 11.528

7.  EMMPRIN promotes melanoma cells malignant properties through a HIF-2alpha mediated up-regulation of VEGF-receptor-2.

Authors:  Faten Bougatef; Suzanne Menashi; Farah Khayati; Benyoussef Naïmi; Raphaël Porcher; Marie-Pierre Podgorniak; Guy Millot; Anne Janin; Fabien Calvo; Céleste Lebbé; Samia Mourah
Journal:  PLoS One       Date:  2010-08-31       Impact factor: 3.240

8.  The pan-Aurora kinase inhibitor, PHA-739358, induces apoptosis and inhibits migration in melanoma cell lines.

Authors:  Lifang Xie; Frank L Meyskens
Journal:  Melanoma Res       Date:  2013-04       Impact factor: 3.599

9.  Links between CD147 function, glycosylation, and caveolin-1.

Authors:  Wei Tang; Sharon B Chang; Martin E Hemler
Journal:  Mol Biol Cell       Date:  2004-06-16       Impact factor: 4.138

10.  EMMPRIN-mediated MMP regulation in tumor and endothelial cells.

Authors:  Stéphanie Caudroy; Myriam Polette; Béatrice Nawrocki-Raby; Jian Cao; Bryan P Toole; Stanley Zucker; Philippe Birembaut
Journal:  Clin Exp Metastasis       Date:  2002       Impact factor: 5.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.